,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,exDividendDate,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,8229 Boone Boulevard,Suite 802,Vienna,VA,22182,United States,703 506 9460,https://cel-sci.com,Biotechnology,Healthcare,"CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.","{'maxAge': 1, 'name': 'Mr. Geert R. Kersten Esq.', 'age': 63, 'title': 'Chief Exec. & Financial Officer, Treasurer and Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 681986, 'exercisedValue': 0, 'unexercisedValue': 503077}",10,10,7,6,9,1693526400,1672444800,86400,4,1.24,1.24,1.19,1.26,1.24,1.24,1.19,1.26,841190400,0.0,1.319156,-2.423077,144548,144548,337800,154950,154950,1.24,1.27,1100,1800,59547724,1.08,4.07,1.6158,2.2785,0.0,0.0,USD,68409768,0.0,45552590,47260100,5458034,5717398,1690761600,1693440000,0.1155,0.03612,0.11943,19.06,0.119799994,0.331,3.8066466,1664496000,1696032000,1688083200,-33831864,-0.79,-0.52,1:25,1497484800,-2.358,ASE,EQUITY,CVM,CVM,Cel-Sci Corporation,CEL-SCI Corporation,439741800,America/New_York,EDT,-14400000,1.26,10.0,7.0,8.5,8.5,2.0,buy,2,5158920,0.109,-29014100,14020965,0.975,1.461,94.804,-0.46179,-1.26432,-25355346,-7644423,-22717518,0.0,0.0,0.0,USD,
1,8229 Boone Boulevard,Suite 802,Vienna,VA,22182,United States,703 506 9460,https://cel-sci.com,Biotechnology,Healthcare,"CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.","{'maxAge': 1, 'name': 'Ms. Patricia B. Prichep', 'age': 71, 'title': 'Sr. VP of Operations & Corp. Sec.', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 286030, 'exercisedValue': 0, 'unexercisedValue': 251668}",10,10,7,6,9,1693526400,1672444800,86400,4,1.24,1.24,1.19,1.26,1.24,1.24,1.19,1.26,841190400,0.0,1.319156,-2.423077,144548,144548,337800,154950,154950,1.24,1.27,1100,1800,59547724,1.08,4.07,1.6158,2.2785,0.0,0.0,USD,68409768,0.0,45552590,47260100,5458034,5717398,1690761600,1693440000,0.1155,0.03612,0.11943,19.06,0.119799994,0.331,3.8066466,1664496000,1696032000,1688083200,-33831864,-0.79,-0.52,1:25,1497484800,-2.358,ASE,EQUITY,CVM,CVM,Cel-Sci Corporation,CEL-SCI Corporation,439741800,America/New_York,EDT,-14400000,1.26,10.0,7.0,8.5,8.5,2.0,buy,2,5158920,0.109,-29014100,14020965,0.975,1.461,94.804,-0.46179,-1.26432,-25355346,-7644423,-22717518,0.0,0.0,0.0,USD,
2,8229 Boone Boulevard,Suite 802,Vienna,VA,22182,United States,703 506 9460,https://cel-sci.com,Biotechnology,Healthcare,"CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.","{'maxAge': 1, 'name': 'Dr. Eyal  Talor Ph.D.', 'age': 66, 'title': 'Chief Scientific Officer', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 340588, 'exercisedValue': 0, 'unexercisedValue': 233318}",10,10,7,6,9,1693526400,1672444800,86400,4,1.24,1.24,1.19,1.26,1.24,1.24,1.19,1.26,841190400,0.0,1.319156,-2.423077,144548,144548,337800,154950,154950,1.24,1.27,1100,1800,59547724,1.08,4.07,1.6158,2.2785,0.0,0.0,USD,68409768,0.0,45552590,47260100,5458034,5717398,1690761600,1693440000,0.1155,0.03612,0.11943,19.06,0.119799994,0.331,3.8066466,1664496000,1696032000,1688083200,-33831864,-0.79,-0.52,1:25,1497484800,-2.358,ASE,EQUITY,CVM,CVM,Cel-Sci Corporation,CEL-SCI Corporation,439741800,America/New_York,EDT,-14400000,1.26,10.0,7.0,8.5,8.5,2.0,buy,2,5158920,0.109,-29014100,14020965,0.975,1.461,94.804,-0.46179,-1.26432,-25355346,-7644423,-22717518,0.0,0.0,0.0,USD,
3,8229 Boone Boulevard,Suite 802,Vienna,VA,22182,United States,703 506 9460,https://cel-sci.com,Biotechnology,Healthcare,"CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.","{'maxAge': 1, 'name': 'Dr. Daniel H. Zimmerman Ph.D.', 'age': 81, 'title': 'Sr. VP of Research & Cellular Immunology', 'yearBorn': 1941, 'fiscalYear': 2022, 'totalPay': 262856, 'exercisedValue': 0, 'unexercisedValue': 118084}",10,10,7,6,9,1693526400,1672444800,86400,4,1.24,1.24,1.19,1.26,1.24,1.24,1.19,1.26,841190400,0.0,1.319156,-2.423077,144548,144548,337800,154950,154950,1.24,1.27,1100,1800,59547724,1.08,4.07,1.6158,2.2785,0.0,0.0,USD,68409768,0.0,45552590,47260100,5458034,5717398,1690761600,1693440000,0.1155,0.03612,0.11943,19.06,0.119799994,0.331,3.8066466,1664496000,1696032000,1688083200,-33831864,-0.79,-0.52,1:25,1497484800,-2.358,ASE,EQUITY,CVM,CVM,Cel-Sci Corporation,CEL-SCI Corporation,439741800,America/New_York,EDT,-14400000,1.26,10.0,7.0,8.5,8.5,2.0,buy,2,5158920,0.109,-29014100,14020965,0.975,1.461,94.804,-0.46179,-1.26432,-25355346,-7644423,-22717518,0.0,0.0,0.0,USD,
4,8229 Boone Boulevard,Suite 802,Vienna,VA,22182,United States,703 506 9460,https://cel-sci.com,Biotechnology,Healthcare,"CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.","{'maxAge': 1, 'name': 'Mr. John  Cipriano', 'age': 80, 'title': 'Sr. VP of Regulatory Affairs', 'yearBorn': 1942, 'fiscalYear': 2022, 'totalPay': 239105, 'exercisedValue': 0, 'unexercisedValue': 176842}",10,10,7,6,9,1693526400,1672444800,86400,4,1.24,1.24,1.19,1.26,1.24,1.24,1.19,1.26,841190400,0.0,1.319156,-2.423077,144548,144548,337800,154950,154950,1.24,1.27,1100,1800,59547724,1.08,4.07,1.6158,2.2785,0.0,0.0,USD,68409768,0.0,45552590,47260100,5458034,5717398,1690761600,1693440000,0.1155,0.03612,0.11943,19.06,0.119799994,0.331,3.8066466,1664496000,1696032000,1688083200,-33831864,-0.79,-0.52,1:25,1497484800,-2.358,ASE,EQUITY,CVM,CVM,Cel-Sci Corporation,CEL-SCI Corporation,439741800,America/New_York,EDT,-14400000,1.26,10.0,7.0,8.5,8.5,2.0,buy,2,5158920,0.109,-29014100,14020965,0.975,1.461,94.804,-0.46179,-1.26432,-25355346,-7644423,-22717518,0.0,0.0,0.0,USD,
